ES2133722T3 - Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos. - Google Patents

Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.

Info

Publication number
ES2133722T3
ES2133722T3 ES95904988T ES95904988T ES2133722T3 ES 2133722 T3 ES2133722 T3 ES 2133722T3 ES 95904988 T ES95904988 T ES 95904988T ES 95904988 T ES95904988 T ES 95904988T ES 2133722 T3 ES2133722 T3 ES 2133722T3
Authority
ES
Spain
Prior art keywords
risk
infection
manufacture
prevent
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904988T
Other languages
English (en)
Inventor
David P Speert
Thomas C Usher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVADEX PHARM Ltd
University of British Columbia
Original Assignee
NOVADEX PHARM Ltd
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVADEX PHARM Ltd, University of British Columbia filed Critical NOVADEX PHARM Ltd
Application granted granted Critical
Publication of ES2133722T3 publication Critical patent/ES2133722T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE PRESENTAN METODOS PARA REDUCIR EL RIESGO O PARA EVITAR INFECCIONES POR ELEMENTOS PATOGENICOS BACTERIANOS "IN VIVO". EN PARTICULAR, SE PRESENTA UN METODO PARA REDUCIR EL RIESGO DE INFECCION POR "P. AERUGINOSA" "IN VIVO" EN ANFITRIONES COMPROMETIDOS TALES COMO PACIENTES DE FIBROSIS CISTICA. LOS METODOS COMPRENDEN EL USO DE DEXTRANO O DE SULFATO DE DEXTRANO COMO INGREDIENTE ACTIVO.
ES95904988T 1993-12-30 1994-12-29 Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos. Expired - Lifetime ES2133722T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17595693A 1993-12-30 1993-12-30
US08/317,228 US5514665A (en) 1993-12-30 1994-10-03 Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans

Publications (1)

Publication Number Publication Date
ES2133722T3 true ES2133722T3 (es) 1999-09-16

Family

ID=26871719

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904988T Expired - Lifetime ES2133722T3 (es) 1993-12-30 1994-12-29 Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.

Country Status (10)

Country Link
US (1) US5514665A (es)
EP (1) EP0737072B1 (es)
AT (1) ATE178798T1 (es)
AU (1) AU1377995A (es)
CA (1) CA2180352C (es)
DE (1) DE69417920T2 (es)
DK (1) DK0737072T3 (es)
ES (1) ES2133722T3 (es)
GR (1) GR3032116T3 (es)
WO (1) WO1995017898A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503423A1 (de) * 1995-02-03 1996-08-08 Beiersdorf Ag Antiadhäsive Wirkstoffe
US6063773A (en) * 1995-09-29 2000-05-16 Polydex Pharmaceuticals Ltd. Cellulose sulfate for use as antimicrobial and contraceptive agent
CA2209342A1 (en) * 1997-06-30 1998-12-30 The University Of British Columbia Use of dextran and other oligomeric saccharides to improve airway clearance
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
FR2781375A1 (fr) * 1998-07-21 2000-01-28 Denis Barritault Composition anti-fibrotique contenant des polymeres ou biopolymeres et leurs utilisations
NL1011680C2 (nl) 1999-03-26 2000-09-27 Nutricia Nv Voedingssamenstellen die licht negatief geladen, niet-verteerbare polysacchariden bevatten en gebruik ervan voor het verminderen van transport door tight junctions.
WO2001015672A2 (en) * 1999-08-26 2001-03-08 Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US6939668B2 (en) * 2001-05-22 2005-09-06 University Health Network Compositions and methods for treatment of lung transplants
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
JP2005535581A (ja) * 2002-05-02 2005-11-24 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肺感染の拡大を制限する処方物
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation
AU2006207322A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
DE102017115870A1 (de) * 2017-07-14 2019-01-17 Strathmann Gmbh & Co. Kg Immunprophylaxe bei Allgemeininfektionen

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141746A (en) * 1970-05-25 1979-02-27 Schweiger Richard Georg Cellulose sulfate esters
JPS5540568B2 (es) * 1972-10-05 1980-10-18
US4177345A (en) * 1974-07-10 1979-12-04 Schweiger Richard Georg Process for preparing a sulfate ester of a polyhydroxy polymer
US5157024A (en) * 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
LU84638A1 (fr) * 1983-02-10 1984-11-08 Oreal Composition capillaire contenant au moins un polymere cationique,un polymere anionique,un sucre et un sel
SE8301609D0 (sv) * 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6168418A (ja) * 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
US4981841A (en) * 1986-04-04 1991-01-01 Allergan, Inc. Methods and materials for use in corneal wound healing
US4826679A (en) * 1986-05-23 1989-05-02 Universite De Montreal Composition and methods for alleviating cystic fibrosis
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
GB8704089D0 (en) * 1987-02-21 1987-03-25 Fisons Plc Method of treatment
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
DE3744119A1 (de) * 1987-12-24 1989-07-06 Basf Ag Verwendung von polysulfatierten heparinen
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
EP0333243A3 (en) * 1988-03-10 1989-09-27 Akzo N.V. Sulphated k5 antigen and sulphated k5 antigen fragments
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
DE3902021A1 (de) * 1989-01-20 1990-07-26 Entec Verwendung von antipeptidergen mitteln, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen prostatakarzinoms
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
AU7681091A (en) * 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
WO1993008810A1 (en) * 1991-11-05 1993-05-13 Carrington Laboratories, Inc. Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
WO1993024505A1 (en) * 1992-05-26 1993-12-09 Alberta Research Council Reducing inflammation by time dependent administration of oligosaccharides glycosides related to blood group determinants
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis

Also Published As

Publication number Publication date
WO1995017898A1 (en) 1995-07-06
GR3032116T3 (en) 2000-04-27
US5514665A (en) 1996-05-07
DE69417920D1 (de) 1999-05-20
EP0737072A1 (en) 1996-10-16
ATE178798T1 (de) 1999-04-15
AU1377995A (en) 1995-07-17
EP0737072B1 (en) 1999-04-14
DE69417920T2 (de) 1999-11-04
CA2180352C (en) 2007-03-20
DK0737072T3 (da) 1999-11-01
CA2180352A1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
ES2133722T3 (es) Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
BR0113861A (pt) Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
AU2001271545A1 (en) Promoting whole body health
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
MXPA01013239A (es) Combinacion de bacterias de acido lactico y su uso para la prevencion y/o tratamiento de infecciones y condiciones inflamatorias.
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
AU4562397A (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
AU2001240578A1 (en) Pharmaceutically active aromatic guanylhydrazones
ES2128404T3 (es) Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2000010998A3 (en) Pyridone antibiotic with improved safety profile
DK1157688T3 (da) Antibakterielle vandige ophthalmiske formuleringer med ofloxacin og chitosan
HK1050203A1 (en) Novel fusidic acid derivatives.
BR9712633A (pt) Método para o tratamento de infecção por streptococcus pneumoniae
WO2024147763A3 (en) Antimicrobial conjugated oligoelectrolytes and methods thereof
WO2000041473A3 (de) Verwendung von 3-isoxazolidinonen und hydroxylaminsäuren zur behandlung von infektionen
WO2023212179A3 (en) Therapeutic compositions for skin disorders and wound repair
RU2002117556A (ru) Способ лечения туберкулеза
WO1992018090A3 (en) Antimicrobial oral compositions
HUP0203876A2 (hu) Topikális alkalmazású gyógyszerkombinációk
GEP20022815B (en) Composition for Treatment of Purulent and Inflammatory Diseases and Method for its Production

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 737072

Country of ref document: ES